DOD-SSR:一种带剂量优化决策与样本量再估计的自适应无缝II/III期设计
提出一种针对多治疗臂无缝II/III期设计的新框架,利用贝叶斯预测成功概率(PPoS)结合替代终点进行治疗臂选择与期中样本量再估计(SSR)。该设计在治疗臂选择正确率、整体统计功效、平均事件数和试验时长方面优于传统独立II/III期设计及未采用SSR或以条件功效选择治疗臂的其他无缝设计。以非小细胞肺癌(NSCLC)案例展示实施。
要点
- 采用贝叶斯预测成功概率(PPoS)同时指导治疗臂选择和期中样本量再估计。
- 期中决策使用替代终点,以提高实践可行性。
- 较传统独立II/III期设计及其他无缝设计,有利治疗臂选择概率更高、统计功效更大、平均事件数和试验时长更少。
核心结论
- 所提出的DOD-SSR设计在有利治疗臂选择概率、整体统计功效、平均事件数和试验时长方面表现更优。
研究设计与样本
- 提出一种针对多治疗臂无缝II/III期设计的新框架,利用贝叶斯预测成功概率(PPoS)结合替代终点进行治疗臂选择与期中样本量再估计(SSR)。
- 以非小细胞肺癌(NSCLC)案例展示所提设计的实施。
主要发现
- 与传统独立II/III期设计相比,所提设计有利治疗臂选择概率更高、整体统计功效更大、平均事件数和试验时长更少。
- 与未采用SSR或以条件功效选择治疗臂的其他无缝II/III期设计相比,所提设计同样表现更优。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The adoption of seamless Phase II/III designs has grown in popularity as a strategy to potentially accelerate the drug development. Making well-informed decisions regarding the drug's potential and addressing important clinical inquiries at the conclusion of the exploratory phase has become a critical step. In response to the increased emphasis on dose optimization, it becomes logical to integrate treatment arm/dose selections into Phase II and implement corresponding design adjustments. Within this framework, employing a fixed sample size presents challenges due to limited information availability before the trial planning and elevated development risks. Furthermore, practical and feasibility considerations have led to the increased utilization of surrogate endpoints for making interim decisions. In this study, we introduce a novel framework for a seamless Phase II/III design involving multiple treatment arms, leveraging Bayesian predictive probability of success (PPoS) for both treatment arm selection and interim sample size re-estimation (SSR) using surrogate endpoints. The proposed design demonstrates improved performance, including a higher likelihood of selecting favorable treatment arm, increased overall statistical power, and reduced average event sizes and trial durations compared to traditional separate Phase II and III designs, as well as other seamless Phase II/III designs without SSR or of which treatment arm selection is based on conditional power. We also showcase the implementation of the proposed design through a case study in non-small cell lung cancer (NSCLC).
引用
- Liu M, Lin J, Zhang Y, et al. DOD-SSR: An Adaptive Seamless Phase II/III Design With Dose Optimization Decision and Sample Size Re-estimation. Stat Med. 2025. PMID: 39921362. doi:10.1002/sim.70014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。